RecruitingNCT06830759

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

EpcoReal: A Multi-country, Prospective Observational Study of Epcoritamab in NHL Comprising Two Patient Cohorts (3L+ (D)LBCL and 3L+ FL)

Sponsor

AbbVie

Enrollment

700 participants

Start Date

Mar 28, 2025

Study Type

OBSERVATIONAL

Conditions

Diffuse Large B Cell Lymphoma Follicular Lymphoma

Summary

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL. Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally. Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This real-world study is collecting data on how well an injectable drug called epcoritamab works in patients with certain types of lymphoma — specifically diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma — who have already tried at least two other treatments. The study tracks outcomes when the drug is used in routine clinical practice. **You may be eligible if...** - You have been diagnosed with DLBCL or follicular lymphoma - Your doctor has already decided to treat you with epcoritamab as third or later line of therapy - The treatment decision was made independently before you were invited to join the study **You may NOT be eligible if...** - You have a condition listed as a contraindication in the approved product label for epcoritamab - You are currently participating in another interventional clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(73)

Hospital Britanico de Buenos Aires /ID# 274419

Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

Hospital Universitario Austral /ID# 274393

Pilar, Buenos Aires, Argentina

Instituto Alexander Fleming /ID# 277284

Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina

Hospital Privado Universitario De Córdoba /ID# 274457

Córdoba, Córdoba Province, Argentina

Hospital Italiano de Buenos Aires /ID# 274418

Buenos Aires, Argentina

Fundacion Argentina contra la Leucemia (FUNDALEU) /ID# 274390

Buenos Aires, Argentina

Nepean Cancer Centre, Nepean Hospital /ID# 277782

Kingswood, New South Wales, Australia

Calvary Mater Newcastle /ID# 277783

Waratah, New South Wales, Australia

Cabrini Hospital Malvern /ID# 277780

Malvern, Victoria, Australia

Krankenhaus Der Barmherzigen Brueder Graz /ID# 273288

Graz, Styria, Austria

Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 273266

Leoben, Styria, Austria

Algemeen Ziekenhuis klina /ID# 273405

Brasschaat, Antwerpen, Belgium

Universitair Ziekenhuis Brussel /ID# 273403

Jette, Brussels Capital, Belgium

Centre Hospitalier Epicura - Hornu /ID# 273406

Boussu, Hainaut, Belgium

Grand Hôpital De Charleroi - Notre Dame /ID# 273728

Charleroi, Hainaut, Belgium

Helora /ID# 273726

La Louvière, Hainaut, Belgium

Groupe Sante CHC - Clinique du MontLegia /ID# 273407

Liège, Liege, Belgium

Ziekenhuis Oost-Limburg, Campus St.-Jan /ID# 273729

Genk, Limburg, Belgium

Vitaz /Id# 273408

Sint-Niklaas, Oost-Vlaanderen, Belgium

AZ Oostende /ID# 273714

Ostend, West-Vlaanderen, Belgium

Umhat Sveti Ivan Rilsky /ID# 274898

Sofiya, Sofia, Bulgaria

University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski /ID# 274893

Pleven, Bulgaria

Acibadem City Clinic Tokuda University Hospital EAD /ID# 273659

Sofia, Bulgaria

Specialized Hospital For Active Treatment Of Haematology Diseases /ID# 274955

Sofia, Bulgaria

Cross Cancer Institute /ID# 271504

Edmonton, Alberta, Canada

The Moncton Hospital /ID# 277230

Moncton, New Brunswick, Canada

Eastern Health - General Hospital /ID# 272062

St. John's, Newfoundland and Labrador, Canada

Health Sciences North /ID# 274738

Greater Sudbury, Ontario, Canada

Kingston General Hospital /ID# 272061

Kingston, Ontario, Canada

Agios Andreas Hospital Patras /ID# 273629

Pátrai, Achaia, Greece

Evangelismos Hospital /ID# 272736

Athens, Attica, Greece

General Hospital of Athens Laiko /ID# 272758

Athens, Attica, Greece

University General Hospital Attikon /ID# 272738

Athens, Attica, Greece

Metaxa Cancer Hospital Of Piraeus /ID# 273623

Piraeus, Attica, Greece

University General Hospital of Alexandroupoli /ID# 272737

Alexandroupoli, Evros, Greece

University Hospital of Ioannina /ID# 272739

Ioannina, Greece

AHEPA University General Hospital of Thessaloniki /ID# 273633

Thessaloniki, Greece

General Hospital of Thessaloniki Hippokrateio /ID# 273635

Thessaloniki, Greece

Papageorgiou General Hospital /ID# 272735

Thessaloniki, Greece

General Hospital Of Thessaloniki G. Papanikolaou /ID# 275323

Thessaloniki, Greece

Tel Aviv Sourasky Medical Center /ID# 271615

Tel Aviv, Tel Aviv, Israel

Hadassah Medical Center-Hebrew University /ID# 271616

Jerusalem, Israel

Rabin Medical Center. /ID# 271614

Petah Tikva, Israel

IRCCS Ospedale San Raffaele /ID# 274789

Milan, Milano, Italy

Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli /ID# 274215

Naples, Napoli, Italy

A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 275283

Turin, Piedmont, Italy

Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 274572

Rome, Roma, Italy

I.R.C.C.S Istituto Tumori Giovanni Paolo II /ID# 274217

Bari, Italy

Ospedale La Maddalena /ID# 274411

Palermo, Italy

Hematologica Alta Especialidad /ID# 275279

Huixquilucan de Degollado, Mexico

Centro de Especialidades Hemato-Oncologicas /ID# 275286

Mexico City, Mexico

Unidade Local de Saude de Coimbra, EPE /ID# 272720

Coimbra, Portugal

Unidade Local de Saúde Trás-os-Montes e Alto Douro /ID# 275404

Vila Real, Portugal

Complejo Hospitalario Universitario A Coruña /ID# 272040

A Coruña, A Coruna, Spain

Institut Català d'Oncologia (ICO) - Badalona /ID# 272043

Badalona, Barcelona, Spain

Hospital Universitari Parc Tauli /ID# 272044

Sabadell, Barcelona, Spain

Hospital Universitario Reina Sofia /ID# 272051

Córdoba, Cordoba, Spain

Hospital Costa del Sol /ID# 272431

Marbella, Malaga, Spain

Hospital Universitario de Navarra /ID# 272041

Pamplona, Navarre, Spain

Hospital Universitario de Valme /ID# 272050

Seville, Sevilla, Spain

Hospital de Manises /ID# 272046

Manises, Valencia, Spain

Hospital Universitario De Burgos /ID# 272066

Burgos, Spain

Hospital General Universitario Morales Meseguer /ID# 272466

Murcia, Spain

Hospital Universitario Nuestra Señora de Candelaria /ID# 272413

Santa Cruz de Tenerife, Spain

Hospital Clinico Universitario de Valladolid /ID# 272042

Valladolid, Spain

Milton Keynes Hospital /ID# 272817

Milton Keynes, Buckinghamshire, United Kingdom

Royal Cornwall Hospital /ID# 272747

Truro, Cornwall, United Kingdom

Cheltenham General Hospital /ID# 272746

Cheltenham, Gloucestershire, United Kingdom

Queen Alexandra Hospital /ID# 272744

Portsmouth, Hampshire, United Kingdom

NHS Lanarkshire /ID# 276471

Airdrie, North Lanarkshire, United Kingdom

Nottingham City Hospital /ID# 272753

Nottingham, Nottinghamshire, United Kingdom

The Christie /ID# 272745

Manchester, United Kingdom

The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 272748

Newcastle upon Tyne, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06830759

Related Trials

A Long-term Extension Study of PCI-32765 (Ibrutinib)

NCT01804686175 locations

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017124 locations

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

NCT067689051 location

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

NCT060433231 location

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

NCT0595202457 locations